Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-07-13
2010-12-14
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07851506
ABSTRACT:
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
REFERENCES:
patent: 4393236 (1983-07-01), Klosa
patent: 4738985 (1988-04-01), Kluger et al.
patent: 4983632 (1991-01-01), Gessa et al.
patent: 5380937 (1995-01-01), Koehler et al.
patent: 5594030 (1997-01-01), Conte et al.
patent: 5753708 (1998-05-01), Koehler et al.
patent: 5840331 (1998-11-01), Van Cauter et al.
patent: 5990162 (1999-11-01), Scharf
patent: 6436998 (2002-08-01), Cacciaglia et al.
patent: 6472431 (2002-10-01), Cook et al.
patent: 7262219 (2007-08-01), Cook et al.
patent: 0 235 408 (1987-09-01), None
patent: 0344704 (1989-06-01), None
patent: 0635265 (1994-07-01), None
patent: 0616804 (1994-09-01), None
patent: 1140061 (2001-10-01), None
patent: 922029 (1963-03-01), None
patent: 57-042651 (1982-03-01), None
patent: 04-049212 (1992-02-01), None
patent: 05-508422 (1993-11-01), None
patent: WO-96/40105 (1996-12-01), None
“U.S. Appl. No. 09/470,570, Final office action mailed Oct. 25, 2001”, 8 pgs.
“U.S. Appl. No. 09/470,570, Notice of allowance mailed Apr. 18, 2002”, 8 pgs.
“U.S. Appl. No. 09/470,870, Non-final office action mailed May 25, 2001”, 9 pgs.
“U.S. Appl. No. 10/194,021, Notice of allowance mailed Mar. 24, 2004”, 8 pgs.
“U.S. Appl. No. 10/841,709, Non-Final Office Action mailed Nov. 30, 2006”, 9 pgs.
“U.S. Appl. No. 10/841,709, Notice of Allowance mailed May 25, 2007”, 5 pgs.
“U.S. Appl. No. 10/841,709, Preliminary Amendment filed May 8, 2004”, 4 pgs.
“U.S. Appl. No. 10/841,709, Response filed Feb. 21, 2007 to Non-Final Office Action mailed Nov. 30, 2006”, 5 pgs.
Arena, C , et al., “Absorption of Sodium Y-Hydroxybutyrate and its Prodrug Y-butyrolactone: relationship between n vitro transport and in vivo absorption”,Journal of Pharmaceutical Sciences, 69(3), (Mar. 1980),356-358.
Bedard, M A., “Nocturnal y-Hydroxybutyrate—Effect on Periodic Leg Movements and Sleep Organization of Narcoleptic Patients”,Clin Neuropharmacol., 12(1), (Feb. 1989),29-36.
Berthier, M , et al., “Possible Involvement of a Gamma-Hydroxybutyric Acid Receptor in Startle Disease”,Acta Paediatr, 83(6), (1994),678-680.
Broughton, Roger, “The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate”,Le Journal Canadien des Sciences Neurologiques, 6(1), (1979),285-289.
Carter Snead, O. , et al., “Ontogeny of Gamma-Hydroxybutyric Acid. Regional Concentration in Developing Rat, Monkey and Human Brain”,Brain Res., 227(4), (1981),579-589.
Ferrara, S D., et al., “Pharmacokinetics of Y-Hydroxybutyric Acid in Alcohol Dependent Patients After Single and Repeated Oral Doses”,Br. J. Clin. Pharmacol., 34(3), (1992),231-235.
Gallimberti, L , “Gamma-Hydroxybutric Acid in the Treatment of Alcohol Dependence: A Double-Blind Study”,Alcohol Clin. Exp. Res., 16(4), (1992),673-676.
Gallimberti, L , “Gamma-hydroxybutyric Acid for Treatment of Alcohol Withdrawal Syndrome”,Clinical Pharmacology, 2(8666), (1989),787-789.
Gessa, G L., et al., “Gamma-hydroxybutyric acid (GHB) for treatment of ethanol dependence”,European Neuropsychopharmacology, 3(3), (1993),224-225.
Gessa, G L., “Gamma-hydroxybutyric Acid in the Treatment of Alcohol Dependence”,Clin. Neuropharm., 15 Suppl 1 Pt A, (1992),303a-304a.
Grove-White, I G., “Critical Flicker Frequency after Small Doses of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate”,Brit. J. Anaesth, 43(2), (1971),110-2.
Grove-White, I G., et al., “Effect of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate on Short-Term Memory”,Brit. J. Anaesth, 43(2), (1971),113-6.
Hasenbos, M A., “Anaesthesia for bullectomy. A technique with spontaneous ventilation and extradural blockade”,Anaesthesia, 40(10), (1985),977-980.
Hoes, M J., “Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man”,Encephale, 6(1), (1980),93-99.
Laborit, H. , “Gamma-Hydroxybutyrate, Succinic Semialdehyde and Sleep”,Laboratoire d'Eutonologie, (1973),257-274.
Ladinsky, Herbert, “Mode of Action of Gamma-Butyrolactone on the Central Cholinergic System”,Naunyn-Schmiedeberg's Arch. Pharmacol., 322, (1983),42-48.
Lammers, G J., “Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study”,Sleep, 16(3), (1993),216-220.
Lapierre, O. , “The Effect of Gamma-Hydroxybutyrate on Nocturnal and Diurnal Sleep of Normal Subjects: Further Considerations on REM Sleep-Triggering Mechanisms”,Sleep, 13, (1990),24-30.
Lee, C R., “Evidence for the B-Oxidation of Orally Administered 4-Hydroxybutyrate in Humans”,Biochemical Medicine, 17(3), (1977),284-291.
Lettieri, J , et al., “Improved Pharmacological Activity via Pro-Drug Modification: Comparative Pharmacokinetics of Sodium Y-Hydroxybutyrate and Y-Butyrolactone”,Research Communications in Chemical Pathology and Pharmacology, 22(1), (1978), 107-118.
Mamelak, M , “Gamma-hydroxybutyrate (GHB): An endogenous Regulator of Energy Metabolism”,Neuroscience and Biobehavioral Reviews, 13(4), (1989),187-198.
Mamelak, M , “Sleep-Inducing Effects of Gammahydroxybutyrate”,The Lancet, 2(7824), (1973),328-329.
Mamelak, Mortimer , “The Effects of Gamma-Hydroxybutyrate on Sleep”,Biological Psychiatry, 12(2), (1977),273-288.
Nema, S , et al., “Excipients and Their Use in Injectable Products”,PDA J. Pharm. Sci. Technol, 51(4), (1997),166-171.
Palatini, P , “Dose Dependent Absorption and Elimination of Gamma-Hydroxybutyric Acid in Healthy Volunteers”,Eur. J. Clin. Pharmacol., 45(4), (1993),353-356.
Roth, et al., “Y-Butyrolactone and Y-Hydroxybutyric Acid-I, Distribution and Metabolism”,Biochemical Pharmacology, 15, (1966),1333-1348.
Scharf, M B., “The Effects and Effectiveness of y-Hydroxybutyrate in Patients with Narcolepsy”,J. Clin. Psychiatry, 46(6), (1985),222-225.
Scrima, et al., “Effect of Gamma-Hydroxybutyrate on a Patient with Obstructive Sleep Apnea”,Sleep Research, 16, (1987),137.
Scrima, et al., “Effect of High Altitude on a Patient with Obstructive Sleep Apnea”,Sleep Research, 16, (1987),427.
Scrima, et al., “Effects of Gamma-Hydroxybutyrate (GHB) on Narcolepsy-Cataplexy Symptoms and MSLT Results in Male and Female Patients”,Association of Professional Sleep Societies, (1988),251.
Scrima, L , et al., “Efficacy of Gamma-Hydroxybutyrate Versus Placebo in Treating Narcolepsy-Cataplexy: Double-blind Subjective Measured”,Biol. Psychiatry, 26(4), (1989),331-343.
Scrima, et al., “Gamma-Hydroxybutyrate Effects on Cataplexy and Sleep Attacks in Narcoleptics”,Sleep Research, 16, (1987),134.
Scrima, L , “The Effects of Y-Hydroxybutyrate on the Sleep of Narcolepsy Patients: A Double-Blind Study”,Sleep, 13(6), (1990),479-490.
Series, F , “Effects of Enhancing Slow-Wave Sleep by Gamma-Hydroxybutyrate on Obsturctive Sleep Apnea”,Am. Rev. Respir. Dis., 145(6), (1992),1378-1383.
Stock, G , “Increase in brain dopamine after axotomy or treatment with Gammahydroxybutyric acid due to elimination of the nerve impulse flow”,Naunyn-Schmiedeberg's Arch. Pharmacol., 278(4), (1973),347-361.
Strong, A J., “gamma-Hydroxybutyric acid and intracranial pressure”,The Lancet, 1(8389), (1984),1304.
Vickers, M D
Cook Harry
Danielson Douglas
Goderstad Colette
Hamilton Martha
Reardan Dayton
Henley, III Raymond J
Jazz Pharmaceuticals, Inc.
Schwegman Lundberg & Woessner, P.A.
LandOfFree
Microbiologically sound and stable solutions of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microbiologically sound and stable solutions of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microbiologically sound and stable solutions of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220885